Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herman Burger

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Cell Cycle (Georgetown, Tex.)|December 22, 2004
Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinibHerman Burger, Kees Nooter
Blood|June 15, 2013
Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?Herman Burger, Ron H J Mathijssen, Alex Sparreboom, et al.
Molecular Pharmacology|February 21, 2002
Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotypePaul W Schenk, Antonius W M Boersma, Mariël Brok, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 22, 2011
Drug transporters of platinum-based anticancer agents and their clinical significanceHerman Burger, Walter J Loos, Karel Eechoute, et al.
Blood|July 15, 2004
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpHerman Burger, Hans van Tol, Antonius W M Boersma, et al.
Cancer Biology & Therapy|May 24, 2005
Effect of ABCG2 genotype on the oral bioavailability of topotecanAlex Sparreboom, Walter J Loos, Herman Burger, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trialErik A C Wiemer, Agnieszka Wozniak, Herman Burger, et al.
Cancer Biology & Therapy|June 16, 2006
Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporterJozien Helleman, Herman Burger, Irene H L Hamelers, et al.
Molecular Pharmacology|July 19, 2003
Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell killPaul W Schenk, Mariel Brok, Antonius W M Boersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Interaction of imatinib with human organic ion carriersShuiying Hu, Ryan M Franke, Kelly K Filipski, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Cell Cycle (Georgetown, Tex.)|December 22, 2004
Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinibHerman Burger, Kees Nooter
Blood|June 15, 2013
Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?Herman Burger, Ron H J Mathijssen, Alex Sparreboom, et al.
Molecular Pharmacology|February 21, 2002
Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotypePaul W Schenk, Antonius W M Boersma, Mariël Brok, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 22, 2011
Drug transporters of platinum-based anticancer agents and their clinical significanceHerman Burger, Walter J Loos, Karel Eechoute, et al.
Blood|July 15, 2004
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpHerman Burger, Hans van Tol, Antonius W M Boersma, et al.
Cancer Biology & Therapy|May 24, 2005
Effect of ABCG2 genotype on the oral bioavailability of topotecanAlex Sparreboom, Walter J Loos, Herman Burger, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trialErik A C Wiemer, Agnieszka Wozniak, Herman Burger, et al.
Cancer Biology & Therapy|June 16, 2006
Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporterJozien Helleman, Herman Burger, Irene H L Hamelers, et al.
Molecular Pharmacology|July 19, 2003
Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell killPaul W Schenk, Mariel Brok, Antonius W M Boersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Interaction of imatinib with human organic ion carriersShuiying Hu, Ryan M Franke, Kelly K Filipski, et al.
Pageof 3